Xilio Therapeutics, Inc. SEC filings XLO

Xilio Therapeutics, Inc. has 357 filings in SEC EDGAR's recent list, going back to Jan 21, 2021. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 12, 2026 (results of operations). The company's fiscal year ends on December 31.

Xilio Therapeutics, Inc. SEC filings
Form Description Filed Period
S-8 Employee stock plan registration Aug 12, 2026 —
10-Q Quarterly report Aug 12, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 12, 2026 Aug 12, 2026
8-K Current report
Officer or director change, Shareholder vote results
Jun 12, 2026 Jun 10, 2026
EFFECT Filing May 29, 2026 —
CORRESP Letter to the SEC May 27, 2026 —
S-3/A Filing May 27, 2026 —
UPLOAD Letter from the SEC May 18, 2026 —
S-3 Shelf registration May 12, 2026 —
10-Q Quarterly report May 12, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 12, 2026 May 12, 2026
ARS Annual report to shareholders Apr 28, 2026 Dec 31, 2025
DEF 14A Proxy statement Apr 28, 2026 Jun 10, 2026
8-K Current report
Officer or director change
Apr 16, 2026 Apr 15, 2026
S-8 Employee stock plan registration Mar 23, 2026 —
10-K Annual report Mar 23, 2026 Dec 31, 2025
8-K Current report
Results of operations
Mar 23, 2026 Mar 23, 2026
8-K Current report
Change to shareholder rights, Bylaw or fiscal year change
Mar 12, 2026 Mar 12, 2026
8-K Current report
Regulation FD disclosure
Mar 9, 2026 Mar 9, 2026
8-K Current report
Shareholder vote results
Feb 24, 2026 Feb 23, 2026
8-K Current report
Material agreement, Regulation FD disclosure
Feb 12, 2026 Feb 11, 2026
424B5 Prospectus supplement Feb 12, 2026 —
424B5 Prospectus supplement Feb 11, 2026 —
DEF 14A Proxy statement Jan 26, 2026 Feb 23, 2026
PRE 14A Preliminary proxy statement Jan 16, 2026 Jan 16, 2026
8-K Current report
Results of operations, Officer or director change
Jan 8, 2026 Jan 6, 2026
8-K Current report
Regulation FD disclosure
Jan 5, 2026 Jan 5, 2026
S-8 Employee stock plan registration Nov 25, 2025 —
8-K Current report
Officer or director change, Shareholder vote results
Nov 25, 2025 Nov 21, 2025
10-Q Quarterly report Nov 13, 2025 Sep 30, 2025
8-K Current report
Results of operations
Nov 13, 2025 Nov 13, 2025
8-K Current report
Regulation FD disclosure
Nov 7, 2025 Nov 7, 2025
DEF 14A Proxy statement Oct 20, 2025 Nov 21, 2025
PRE 14A Preliminary proxy statement Oct 10, 2025 Nov 21, 2025
8-K Current report
Listing notice
Oct 3, 2025 Oct 2, 2025
8-K Current report
Other events
Sep 9, 2025 Sep 9, 2025
8-K Current report
Listing notice
Aug 28, 2025 Aug 22, 2025
10-Q Quarterly report Aug 14, 2025 Jun 30, 2025
8-K Current report
Results of operations
Aug 14, 2025 Aug 14, 2025
8-K Current report
Shareholder vote results
Jun 12, 2025 Jun 10, 2025
8-K Current report
Officer or director change
Jun 10, 2025 Jun 10, 2025
DEFA14A Additional proxy material Jun 3, 2025 —
8-K Current report
Material agreement, Regulation FD disclosure, Other events
Jun 3, 2025 Jun 2, 2025
424B5 Prospectus supplement Jun 3, 2025 —
424B5 Prospectus supplement Jun 2, 2025 —
8-K Current report
Regulation FD disclosure, Other events
Jun 2, 2025 May 31, 2025
EFFECT Filing May 8, 2025 —
10-Q Quarterly report May 8, 2025 Mar 31, 2025
8-K Current report
Results of operations
May 8, 2025 May 8, 2025
CORRESP Letter to the SEC May 6, 2025 —
S-3/A Filing May 6, 2025 —
ARS Annual report to shareholders Apr 28, 2025 Dec 31, 2024
DEFA14A Additional proxy material Apr 28, 2025 —
DEF 14A Proxy statement Apr 28, 2025 Jun 10, 2025
PRE 14A Preliminary proxy statement Apr 18, 2025 Jun 10, 2025
8-K Current report
Listing notice
Apr 8, 2025 Apr 4, 2025
UPLOAD Letter from the SEC Mar 17, 2025 —
S-3 Shelf registration Mar 11, 2025 —
8-K Current report
Material agreement
Mar 11, 2025 Mar 11, 2025
424B5 Prospectus supplement Mar 11, 2025 —
S-8 Employee stock plan registration Mar 11, 2025 —
10-K Annual report Mar 11, 2025 Dec 31, 2024
8-K Current report
Results of operations
Mar 11, 2025 Mar 11, 2025
8-K Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
Feb 12, 2025 Feb 10, 2025
8-K Current report
Regulation FD disclosure, Other events
Jan 21, 2025 Jan 21, 2025
8-K Current report
Unregistered share sale, Regulation FD disclosure, Other events
Dec 19, 2024 Dec 18, 2024
10-Q Quarterly report Nov 7, 2024 Sep 30, 2024
8-K Current report
Results of operations, Regulation FD disclosure, Other events
Nov 7, 2024 Nov 7, 2024
8-K Current report
Listing notice
Sep 13, 2024 Sep 10, 2024
10-Q Quarterly report Aug 8, 2024 Jun 30, 2024
8-K Current report
Results of operations
Aug 8, 2024 Aug 8, 2024
8-K Current report
Shareholder vote results
Jun 17, 2024 Jun 13, 2024
8-K Current report
Officer or director change
Jun 13, 2024 Jun 13, 2024
10-Q Quarterly report May 14, 2024 Mar 31, 2024
8-K Current report
Results of operations
May 14, 2024 May 14, 2024
EFFECT Filing May 6, 2024 —
CORRESP Letter to the SEC May 2, 2024 —
UPLOAD Letter from the SEC May 2, 2024 —
S-3 Shelf registration Apr 30, 2024 —
ARS Annual report to shareholders Apr 25, 2024 Dec 31, 2023
DEFA14A Additional proxy material Apr 25, 2024 —
DEF 14A Proxy statement Apr 25, 2024 Jun 13, 2024
424B5 Prospectus supplement Apr 15, 2024 —
S-8 Employee stock plan registration Apr 1, 2024 —
10-K Annual report Apr 1, 2024 Dec 31, 2023
8-K Current report
Results of operations
Apr 1, 2024 Apr 1, 2024
8-K Current report
Other events
Mar 28, 2024 Mar 28, 2024
8-K Current report
Material agreement, Results of operations, Exit or restructuring costs, Unregistered share sale, Regulation FD disclosure, Other events
Mar 28, 2024 Mar 27, 2024
8-K Current report
Listing notice
Jan 19, 2024 Jan 19, 2024
8-K Current report
Officer or director change
Jan 3, 2024 Jan 1, 2024
8-K Current report
Other events
Dec 7, 2023 Dec 7, 2023
10-Q Quarterly report Nov 9, 2023 Sep 30, 2023
8-K Current report
Results of operations
Nov 9, 2023 Nov 9, 2023
10-Q/A Amended quarterly report Nov 9, 2023 Jun 30, 2023
10-Q/A Amended quarterly report Nov 9, 2023 Mar 31, 2023
10-K/A Amended annual report Nov 9, 2023 Dec 31, 2022
8-K Current report
Other events
Nov 3, 2023 Nov 3, 2023
8-K Current report
Officer or director change, Other events
Sep 5, 2023 Aug 30, 2023
10-Q Quarterly report Aug 14, 2023 Jun 30, 2023
8-K Current report
Results of operations, Regulation FD disclosure
Aug 14, 2023 Aug 14, 2023
8-K Current report
Officer or director change
Aug 3, 2023 Aug 3, 2023
8-K Current report
Shareholder vote results
Jun 13, 2023 Jun 8, 2023
8-K Current report
Regulation FD disclosure, Other events
May 25, 2023 May 25, 2023
10-Q Quarterly report May 9, 2023 Mar 31, 2023
8-K Current report
Results of operations
May 9, 2023 May 9, 2023
ARS Annual report to shareholders Apr 25, 2023 Dec 31, 2022
DEFA14A Additional proxy material Apr 25, 2023 —
DEF 14A Proxy statement Apr 25, 2023 Jun 8, 2023
8-K Current report
Officer or director change, Bylaw or fiscal year change
Apr 3, 2023 Mar 28, 2023
S-8 Employee stock plan registration Mar 2, 2023 —
10-K Annual report Mar 2, 2023 Dec 31, 2022
8-K Current report
Results of operations
Mar 2, 2023 Mar 2, 2023
8-K Current report
Regulation FD disclosure
Jan 9, 2023 Jan 9, 2023
8-K Current report
Officer or director change
Dec 23, 2022 Dec 19, 2022
EFFECT Filing Nov 18, 2022 —
CORRESP Letter to the SEC Nov 16, 2022 —
UPLOAD Letter from the SEC Nov 15, 2022 —
S-3 Shelf registration Nov 9, 2022 —
10-Q Quarterly report Nov 9, 2022 Sep 30, 2022
8-K Current report
Results of operations, Regulation FD disclosure
Nov 9, 2022 Nov 9, 2022
8-K Current report
Officer or director change
Sep 15, 2022 Sep 15, 2022
10-Q Quarterly report Aug 9, 2022 Jun 30, 2022
8-K Current report
Results of operations
Aug 9, 2022 Aug 9, 2022
8-K Current report
Officer or director change
Jul 28, 2022 Jul 25, 2022
8-K Current report
Officer or director change
Jun 16, 2022 Jun 15, 2022
8-K Current report
Shareholder vote results
Jun 13, 2022 Jun 9, 2022
10-Q Quarterly report May 12, 2022 Mar 31, 2022
8-K Current report
Results of operations, Regulation FD disclosure
May 12, 2022 May 12, 2022
DEFA14A Additional proxy material Apr 26, 2022 —
DEF 14A Proxy statement Apr 26, 2022 Jun 9, 2022
S-8 Employee stock plan registration Mar 1, 2022 —
10-K Annual report Mar 1, 2022 Dec 31, 2021
8-K Current report
Results of operations
Mar 1, 2022 Mar 1, 2022
8-K Current report
Officer or director change
Feb 4, 2022 Feb 3, 2022
8-K Current report
Officer or director change
Jan 6, 2022 Jan 4, 2022
10-Q Quarterly report Dec 2, 2021 Sep 30, 2021
8-K Current report
Results of operations
Dec 2, 2021 Dec 2, 2021
8-K Current report
Bylaw or fiscal year change
Oct 26, 2021 Oct 26, 2021
S-8 Employee stock plan registration Oct 25, 2021 —
SEC STAFF LETTER Filing Oct 22, 2021 —
424B4 Prospectus Oct 22, 2021 —
EFFECT Filing Oct 21, 2021 —
CERT 8a cert Oct 21, 2021 —
S-1/A Amended registration statement Oct 20, 2021 —
CORRESP Letter to the SEC Oct 19, 2021 —
CORRESP Letter to the SEC Oct 19, 2021 —
8-A12B Filing Oct 18, 2021 —
CORRESP Letter to the SEC Oct 18, 2021 —
S-1/A Amended registration statement Oct 18, 2021 —
UPLOAD Letter from the SEC Oct 13, 2021 —
CORRESP Letter to the SEC Oct 1, 2021 —
S-1 Registration statement Oct 1, 2021 —
UPLOAD Letter from the SEC Sep 23, 2021 —
DRSLTR Filing Sep 14, 2021 —
DRS/A Filing Sep 14, 2021 —
SEC STAFF LETTER Filing Jun 25, 2021 —
UPLOAD Letter from the SEC Jun 21, 2021 —
DRS Filing May 24, 2021 —
D Filing Feb 26, 2021 —
D Filing Jan 21, 2021 —

Showing 160 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
XLO (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Waltham, MA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1840233

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.